Evidence map›Paper›PMID 37663424›Full record

ReviewJournal of reproduction & infertility

The Role of MicroRNAs in Development of Endometrial Cancer: A Literature Review.

Somasundaram Indumati, Birajdar Apurva, Gaur Gaurav, Singh Nehakumari, Vyas Nishant

Open access · greenAbstract readReview
In one paragraph

Review in Journal of reproduction & infertility. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. MicroRNA Crossroads in PCOS and Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2026
    Review
  2. Article
  3. miRNA in Endometriosis-A New Hope or an Illusion?Journal of clinical medicine · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Somasundaram IndumatiDepartment of Stem Cell and Regenerative Medicine, D.Y. Patil Education Society, Kolhapur, India.
Birajdar ApurvaDepartment of Stem Cell and Regenerative Medicine, D.Y. Patil Education Society, Kolhapur, India.
Gaur GauravLogical Life science, Maharashtra, India.
Singh NehakumariLogical Life science, Maharashtra, India.
Vyas NishantLogical Life science, Maharashtra, India.
D.Y. Patil Education Society · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial cancer (EC) ranks as the second most common gynaecological cancer worldwide. EC patients are diagnosed at an early clinical stage and generally have a good prognosis. Therefore, there is a dire need for development of a specific marker for early detection of endometrial adenocarcinoma. The development of EC is conditioned by a multistep process of oncogenic upregulation and tumor suppressor downregulation as shown by molecular genetic evidence. In this setting, microRNAs appear as significant regulators of gene expression and several variations in the expression of microRNAs have been implicated in normal endometrium, endometrial tissue, metrorrhagia, and endometrial cancer. Furthermore, microRNAs act as highly precise, sensitive, and robust molecules, making them potential markers for diagnosing specific cancers and their progression. With the rising incidence of EC, its management remains a vexing challenge and diagnostic methods for the disease are limited to invasive, expensive, and inaccurate tools. Therefore, the prospect of exploiting the utility of microRNAs as potential candidates for diagnosis and therapeutic use in EC seems promising.

Indexed as

BiomarkersEndometrial neoplasmsGene therapyMicroRNAsSignal transduction

Identifiers

PMID37663424
PMCPMC10471942
OpenAlexW4385388149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.